News Archive

2010

26.04.2010
Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canada
Nycomed and Merck & Co. announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas® (roflumilast)

2009

10.10.2009
Association of symptoms of chronic bronchitis and frequent flu-like illnesses with stroke
Grau AJ, Preusch MR, Palm F, Lichy C, Becher H, Buggle F.

01.10.2009
Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk
Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD.

06.04.2009
AstraZeneca´s SYMBICORT®
AstraZeneca receives FDA Complete Response Letter on SYMBICORT® for the treatment of asthma in children 6 to 11 years old

01.04.2009
Clinical definition of COPD exacerbations and classification of their severity
Caramori G, Adcock IM, Papi A.

25.03.2009
GlaxoSmithKline (GSK)
GlaxoSmithKline global collaboration identifies two new genes for COPD - Smokers with gene variants at high risk of developing respiratory condition - Results provide new insight to disease process

01.03.2009
The association between home and vehicle environmental tobacco smoke (ETS) and chronic bronchitis in a Canadian population: the Canadian Community Health Survey, 2005
Evans J, Chen Y.

27.02.2009
AstraZeneca´s SYMBICORT®
FDA approves SYMBICORT® for Chronic Obstructive Pulmonary Disease (COPD)

01.02.2009
Traffic-related air pollution associated with prevalence of asthma and COPD/chronic bronchitis. A cross-sectional study in Southern Sweden
Lindgren A, Stroh E, Montnémery P, Nihlén U, Jakobsson K, Axmon A.

2008

15.12.2008
Chronic bronchitis and acute infections as new risk factors for ischemic stroke and the lack of protection offered by the influenza vaccination
Piñol-Ripoll G, de la Puerta I, Santos S, Purroy F, Mostacero E.

10.09.2008
AstraZeneca´s SYMBICORT®
Newly released data on onset of effect and patient perception with SYMBICORT® in adults with asthma

30.04.2008
FDA approves Advair 250/50 for reduction of exacerbations in patients with COPD
Advair 250/50 now the only treatment approved to both reduce exacerbations and improve lung function

2007

05.03.2007
Pierre Fabre / Zambon
PIERRE FABRE TO DISTRIBUTE PRODUCTS OF ZAMBON S.P.A. IN GERMANY